Pharmacy Times September 28, 2022
Aislinn Antrim, Associate Editor

New research has shown significant promise for the use of CAR T-cell therapies in solid tumors.

At the 2022 International Cancer Immunotherapy Conference in New York City, keynote speaker Crystal L. Mackall, MD, reviewed several studies with new findings about how future chimeric antigen receptor (CAR) T-cell therapy research could minimize the limitations of these treatments.

Mackall said it has been an exciting time in immuno-oncology research, particularly around CAR T-cell therapies. As of July 31, 2022, Mackall said there are 12 approvals, 6 products, and 2 targets in the CAR T space.

“I think, even for someone like myself, who was wowed by the first patient treated…with current T-cell therapies, I didn’t expect that their momentum and impact 10...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article